Evidence map›Paper›PMID 37600660›Full record

ReviewFrontiers in genetics2023

HMG-boxes, ribosomopathies and neurodegenerative disease.

Tom Moss, Mark S LeDoux, Colyn Crane-Robinson

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 3 countries.

Tom MossLaboratory of Growth and Development, St-Patrick Research Group in Basic Oncology, Cancer Division of the Quebec University Hospital Research Centre, Québec, QC, Canada.
Mark S LeDouxDepartment of Psychology, University of Memphis, Memphis, TN, United States.
Colyn Crane-RobinsonBiophysics Laboratories, School of Biology, University of Portsmouth, Portsmouth, United Kingdom.
Université Laval · CAUniversity of Memphis · USUniversity of Portsmouth · GB

Funding

Pathobiology and Treatment of the UBTF E210K Neuroregression SyndromeR56NS123059 · NINDS · UNIVERSITY OF MEMPHIS · PI LEDOUX, MARK S · 2021 to 2021
$415k
NINDS NIH HHS R56 NS123059
6 · The paper itself

Abstract

The UBTF E210K neuroregression syndrome is a predominantly neurological disorder caused by recurrent

Indexed as

neuroregression syndromeribosome biogenesisribosomopathyRNA polymerase I (POLR1)TBP-TAF complex SL1UBTF-E210Kupstream binding factor (UBF/UBTF)

Identifiers

PMID37600660
PMCPMC10435976
OpenAlexW4385519837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.